Osteosarcoma
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Published in Medical Letter on the CDC and FDA, October 12th, 2008
IDM Pharma, Inc. (NASDAQ:IDMI) announced that it met with representatives of the Committee for Medicinal Products for Human Use (CHMP) and Secretariat of the European Medicines Agency (EMEA) on September 25th, following the CHMP's September meeting where CHMP considered the Company's Marketing Authorization Application (MAA) for mifamurtide (L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
Based on discussions at that meeting, the Company has been invited to present to the CHMP Scientific Advisory Group on Oncology (SAG-O) and to the CHMP to review...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Massachusetts General Hospital
Study confirms benefit of combination therapy for Alzheimer's disease - Alzheimer Disease
Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease - Anxiety Disorders
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression - Celsion Corporation
Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial - Endoscopy
Study Published in Gastrointestinal Endoscopy Features Computer-Assisted Personalized Sedation (CAPS) - Obesity and Diabetes
First Reported Head-to-Head Study Showed BYETTAŽ (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia (sitagliptin) in Patients With Type 2 Diabet - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
